The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab
Open accessAbstract
To the Editor: Inhibition of immune checkpoints with the use of antibodies targeting programmed cell death 1 (PD-1) or monoclonal antibodies against cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) has been used clinically in patients with various types of cancer. In the limited number of reported cases in which these antibodies have been used in patients who have undergone kidney transplantation,1 these agents have been associated with cell-mediated and antibody-mediated rejection (see Table S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). We report on a patient who received a renal transplant from a living related donor. . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, several transplant patients experienced a tumor response without rejection when their immunosuppressive regimen contained sirolimus.165,169,170”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [170]
In the citing paper
“For patients with kidney transplants, anecdotal use of mTOR inhibition (mTORi) as primary prevention was reported12,13.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [13]
Citations
Cites
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
Lipson, E. J., Bagnasco, S. M., Moore, J. D., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509268 · Cited by 278
Rapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Cited by
Sorted by citations
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713
Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,536
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
Esfahani, K., Roudaia, L., Buhlaiga, N., Rincon, S. V. D., Papneja, N., & Miller, W. H. (2020) · Current Oncology · doi:10.3747/co.27.5223 · Cited by 1,000
Post-Transplantation Lymphoproliferative Disorders in Adults
Dierickx, D., & Habermann, T. M. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1702693 · Cited by 488
Metadata
- Authors
- Barnett, R., Barta, V. S., & Jhaveri, K. D.
- Affiliations
- Hofstra University (US)
- ORCID
- Jhaveri, Kenar D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-01-12
- Volume
- 376
- Issue
- 2
- Pages
- 191-192
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2578082697
- Cited by
- 136
- References
- 5
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 14 · 2023: 6 · 2022: 18 · 2021: 12 · 2020: 26 · 2019: 16 · 2018: 21 · 2017: 17
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- nivolumab, kidney transplantation, immune checkpoint inhibitors, graft rejection, antibody-mediated rejection, cell-mediated rejection, living related donors, renal allograft function
- MeSH terms
- Nivolumab, Adenocarcinoma, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Duodenal Neoplasms, Humans, Liver Neoplasms, Male, Kidney Transplantation, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
